{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:37:55Z","timestamp":1763620675259,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.transproceed.2019.10.035","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T17:02:25Z","timestamp":1580749345000},"page":"604-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report"],"prefix":"10.1016","volume":"52","author":[{"given":"Kazunobu","family":"Shinoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotaro","family":"Kitaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Asanuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2019.10.035_bib1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/TP.0000000000001192","article-title":"Outcomes of solid organ transplant recipients with preexisting malignancies in remission: a systematic review and meta-analysis","volume":"101","author":"Acuna","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2019.10.035_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2019.10.035_bib3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2019.10.035_bib4","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","article-title":"Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients","volume":"22","author":"Marcolino","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.transproceed.2019.10.035_bib5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2004.02.009","article-title":"EAU guidelines on renal transplantation","volume":"47","author":"K\u00e4lble","year":"2005","journal-title":"Eur Urol"},{"issue":"Suppl. 7","key":"10.1016\/j.transproceed.2019.10.035_bib6","first-page":"1","article-title":"European Expert Group on Renal Transplantation), European Renal Association (ERA-EDTA), European Society for Organ Transplantation (ESOT). European best practice guidelines for renal transplantation (part 1)","volume":"15","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2019.10.035_bib7","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/ndt\/gfu216","article-title":"European renal best practice guideline on kidney donor and recipient evaluation and perioperative care","volume":"30","author":"Abramowicz","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2019.10.035_bib9","first-page":"29","article-title":"A\u00a0successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib","volume":"2","author":"Martino","year":"2013","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.transproceed.2019.10.035_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2019.10.035_bib11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A\u00a0new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.transproceed.2019.10.035_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.transproceed.2019.10.035_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ndt\/17.4.685","article-title":"Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571","volume":"17","author":"Kitiyakara","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2019.10.035_bib14","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/1042819031000079140","article-title":"Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia","volume":"44","author":"Pou","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transproceed.2019.10.035_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.leukres.2009.07.009","article-title":"Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature","volume":"34","author":"Gafter-Gvili","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.transproceed.2019.10.035_bib16","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0002-9440(10)65484-3","article-title":"Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury","volume":"155","author":"Nakagawa","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.transproceed.2019.10.035_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.transproceed.2019.10.035_bib18","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"Deremer","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.transproceed.2019.10.035_bib19","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519310760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519310760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:33:25Z","timestamp":1758576805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134519310760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0041134519310760"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2019.10.035","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2019.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}